Beth Israel Deaconess Medical Center

Sorting 5 by

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

AZD6738

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more
  • Kinase Inhibitor
  • Phase 1

Accepting patients

Maintenance Ruxolitinib

Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Learn more
  • JAK2 Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Maintenance
  • Phase 2

Accepting patients

SAR443579

An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Learn more
  • Trispecific NK Engager
  • Phase 1/2
  • Has results

Accepting patients

SEA-CD70

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Learn more
  • Monoclonal Antibody
  • Phase 1